In follow-up to legal dispute, two commercial trials are halted by FDA on anti-VEGF trials in AMD and diabetic retinopathy

REGENXBIO Inc. (Nasdaq: RGNX), a clinical stage gene therapy company, has halted a FDA clinical trial on an AAV anti-VEGF product (RGX-314) for wet AMD in the US. The company reported a 8-K filing at the Securities Exchange Commission which stated that an initiation of a Phase IIb trial for RGX-314 has been notified from the FDA regarding certain third-party commercially-available surgical devices that were used to deliver RGX-314 in the Phase I/IIa trial. The company stated that the notification is not related to the RGX-314 gene therapy itself and that the company has not received reports of any device-related concerns or complications in the subjects already dosed in the trial. Commenting on the report, Mr. Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO, said that “we are working with the FDA to address this matter, and as a result, we now plan to initiate our Phase IIb trial for RGX-314 in wet AMD and file our IND for diabetic retinopathy in Q1 2020”.


RGX-314 is being developed as a potential treatment for wet AMD and diabetic retinopathy (DR) is being evaluated in the Phase I/IIa, multi-center, open-label, multiple-cohort, dose‑escalation study in adult subjects in the United States. The study is designed to evaluate five escalating doses of RGX-314, with six subjects in the first three dose cohorts and twelve subjects in the fourth and fifth dose cohorts. Subjects were enrolled into all dose cohorts independent of their neutralizing antibody titers to AAV and did not receive prophylactic immune suppressive oral corticosteroid therapy before or after administration of RGX-314. In a previous interim report on October 11th, 2019, 75% of subjects (9/12) in cohort 5 remain free of anti-VEGF injections, with mean improvement in vision and retinal thickness and additionally reported to observe durable effects on vision and retinal thickness over 18 months in cohort 3. According to the company, 50% of the subjects (3/6) remain free of anti-VEGF injections at 18 months after RGX-314 administration. Secondary endpoints include visual acuity, retinal thickness on spectral domain optical coherence tomography (SD‑OCT), ocular RGX-314 protein expression, and the need for additional anti-VEGF therapy. Following completion of the primary study period, subjects enter a follow-up period and will continue to be assessed until week 106 for long-term safety and durability of effect.


REGENEX has now reported to sue the FDA in US District Court documents, declaring that the company has challenged the FDA for a clinical hold order. According to the dispute, the company stated that the FDA action ‘is contrary to law and arbitrary and capricious because it did not follow the statute or its own regulations, nor did FDA offer a reasoned explanation for issuing a clinical hold without advance warning”. FDA is due to respond a written explanation to the company in due course.

17 thoughts on “In follow-up to legal dispute, two commercial trials are halted by FDA on anti-VEGF trials in AMD and diabetic retinopathy”

  1. Do you mind if I quote a few of your posts as long as
    I provide credit and sources back to your weblog? My blog site is in the exact same area of interest as yours and my users would truly benefit from a lot
    of the information you present here. Please let me know
    if this ok with you. Many thanks!

  2. For the reason that the admin of this web page is working, no doubt
    very soon it will be well-known, due to its feature contents.

  3. Thank you for every other fantastic article. The place
    else could anyone get that kind of information in such an ideal manner
    of writing? I’ve a presentation subsequent week, and I’m at the search for such info.

  4. I’m really enjoying the design and layout of your site.
    It’s a very easy on the eyes which makes it much more enjoyable for me to come here and
    visit more often. Did you hire out a developer to create your theme?
    Great work!

  5. I just want to mention I’m beginner to blogging and certainly liked your web-site. More than likely I’m going to bookmark your website . You surely come with excellent article content. Many thanks for sharing your web site.

  6. There are a few interesting points soon enough in this article but I don’t determine if every one of them center to heart. There is certainly some validity but I am going to take hold opinion until I investigate it further. Excellent post , thanks so we want far more! Added to FeedBurner too

  7. I want to show some appreciation to this writer for rescuing me from this scenario. Because of scouting through the world wide web and finding methods that were not powerful, I was thinking my life was gone. Existing without the approaches to the problems you’ve resolved all through your report is a critical case, as well as those that might have in a negative way damaged my career if I had not come across the blog. Your primary competence and kindness in dealing with the whole thing was valuable. I am not sure what I would’ve done if I hadn’t come upon such a thing like this. I am able to at this time look forward to my future. Thanks very much for this impressive and result oriented guide. I won’t think twice to recommend the blog to any person who should have direction about this problem.

  8. After research a few of the post on your internet site now, and also I really like your method of blogging. I bookmarked it to my book marking web site listing and will certainly be checking back soon. Pls have a look at my internet site also and let me know what you assume.

Leave a Reply

Your email address will not be published.